RECRUITINGOBSERVATIONAL

PRO for Fighting FT in Ovarian Cancer

Patient-Reported Outcome for Fighting Financial Toxicity in Ovarian Cancer

About This Trial

Non-profit, multicenter, prospective, observational study. This study aims to evaluate whether the articulated treatment algorithm that is now possible for OC patients does produce tangible changes of financial distress over the time and whether the determinants of financial distress change their relative weight over the time.

Who May Be Eligible (Plain English)

Who May Qualify: - Written willing to sign a consent form provided; - Women ≥18 years; - Histologically or citologically confirmed diagnosis of epithelial ovarian, fallopian tube or peritoneal cancer stage IC-IV according to FIGO staging system; - Patients who are close to begin any type of medical treatment against ovarian cancer. Who Should NOT Join This Trial: - Major cognitive dysfunction or psychiatric disorders; - Patients with epithelial ovarian, fallopian tube or peritoneal cancer candidate exclusively to follow-up; - Patients who have received more than 4 previous lines of medical treatment (maintenance treatments do not represent a line). Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Written informed consent provided; * Women ≥18 years; * Histologically or citologically confirmed diagnosis of epithelial ovarian, fallopian tube or peritoneal cancer stage IC-IV according to FIGO staging system; * Patients who are close to begin any type of medical treatment against ovarian cancer. Exclusion Criteria: * Major cognitive dysfunction or psychiatric disorders; * Patients with epithelial ovarian, fallopian tube or peritoneal cancer candidate exclusively to follow-up; * Patients who have received more than 4 previous lines of medical treatment (maintenance treatments do not represent a line).

Treatments Being Tested

OTHER

Questionnaires

The PROFFIT questionnaire is a PRO instrument composed by 16 items encompassing all the major life domains where FT can be expressed and is formed by two type of items: (1) outcome (items 1-7) and (2) determinants (items 8-16); EORTC QLQ-C30 questionnaire (items 29-30) and OV28 (items 55-58); PRO-CTCAE: short list of 43 symptoms relevant for ovarian cancer

Locations (1)

Nation Cancer Institute of Naples, Division of Medical Oncology - Uro-Gynecology Department

Naples, Italy